Global Navigation
Recent news
-
AZ’s UK research job losses ‘bad news’ for country’s industry say unions
GMB and Unite say 350 job cuts in R&D at Chesire facility will damage UK industry, although ABPI remains optimistic
03 Feb 2012 -
Mobile health roundup
Includes an Italian remote patient monitoring project, a new Blackberry app from Galderma UK and the winning entry in Eyeforpharma’s mobile health competition
03 Feb 2012 -
Victoza drives Novo Nordisk growth in 2011
Diabetes portfolio encourages 12 per cent increase in revenues for Denmark-based firm
03 Feb 2012 -
Merck returns to profit in Q4
Gains in diabetes division, but generics pose threat for 2012
03 Feb 2012 -
Mitchell Gold steps down as CEO and president of Dendreon
Former Savient CEO and Lilly senior VP John Johnson replaces Gold who remains at Dendreon as executive chair
03 Feb 2012 -
EMA prepares for major changes to European pharmacovigilance legislation
New measures will encourage greater transparency and allow patients in any European Member State to report adverse reactions
03 Feb 2012 -
Caudex Medical makes senior hires
Appoints Andy Bowman and Gary Burd
03 Feb 2012 -
AstraZeneca to cut 7,300 jobs in global restructuring
Sales, research and supply chain operations among those affected
02 Feb 2012 -
Gamification guide for pharma launched
Explains how to use game mechanics to solve problems and engage audiences in healthcare
02 Feb 2012 -
Pfizer recalls contraceptive pills after packaging blunder
One million packages of Lo/Ovral-28, Norgestrel and Ethinyl Estradiol voluntarily withdrawn in US after mix-up leads to risk of unwanted pregnancy
02 Feb 2012 -
Personalised medicine for cystic fibrosis cleared in US
Vertex' 'breakthrough' Kalydeco is first treatment to target genetic mutation in the disease
02 Feb 2012 -
Abiraterone too expensive for NHS, says NICE
Price of J&J's prostate cancer treatment too high to justify use in UK
02 Feb 2012 -
Income up for Roche despite dip in sales
Swiss firm looks to new products and purchase of Illumina to compensate for revenue decline
02 Feb 2012 -
Dan Zabrowski takes over as head of Roche Applied Science
Former global head of partnering succeeds Paul Brown
02 Feb 2012 -
Pfizer lost $5bn to generics in 2011
Pharma giant’s fourth quarter hit particularly hard after Lipitor’s November US patent expiry
01 Feb 2012 -
Astellas, Medivation prostate cancer drug beats expectations in phase III
Results come as Astellas records net income increase of 24 per cent in the fiscal third quarter
01 Feb 2012 -
Boehringer Ingelheim to launch new pharma blog
The Future Just Happened builds on its Facebook 'content curation' deal with PSFK
01 Feb 2012 -
Generics take toll on Lilly’s 2011 financial results
Sales of antipsychotic Zyprexa fall 44 per cent in fourth quarter
01 Feb 2012 -
European Commission drops Servier misinformation investigation
Charges part of wider anticompetitive behaviour case involving generic perindopril
01 Feb 2012 -
European healthcare logistics association launched
EALTH will lobby for greater awareness of the health supply chain sector
01 Feb 2012 -
Napp hires Dietmar Leitner as managing director
Former general manager at Mundipharma succeeds Antony Mattessich
01 Feb 2012 -
Pfizer in talks to sell Kent, UK research facility
Pharma firm confirms advanced discussions with property consortium for sale of Discovery Park
31 Jan 2012 -
SkyePharma's CEO Axel Mueller resigns
He will be replaced by the drug delivery company’s chief financial officer Peter Grant
31 Jan 2012 -
James Murdoch to step down from GSK's board
Announcement follows 2011’s damaging revelations of phone hacking at UK newspaper the News of the World
31 Jan 2012 -
WHO partners with 13 pharma firms to tackle tropical diseases
Pfizer, Sanofi and GSK among the companies pledging help to eradicate neglected tropical diseases like rabies and leprosy
31 Jan 2012 -
Cell Therapeutics pulls Pixuvri filing for non-Hodgkin's lymphoma
Additional time needed to prepare for FDA review
31 Jan 2012 -
Roche wins early US approval for skin cancer drug Erivedge
Erivedge is the first drug specifically registered to treat basal cell carcinoma
31 Jan 2012 -
BMS records double-digit profit growth for 2011
Meanwhile the company expects new launches to counter loss of Plavix patent in 2012
30 Jan 2012 -
Amylin, Alkermes' Bydureon approved in US on third atttempt
Type 2 diabetes drug will be rival to Novo Nordisk’s Victoza
30 Jan 2012 -
Non-branded digital resources are "strong drivers of action"
Over 40 per cent of online US adults discuss medication with a healthcare professional after using a pharma-sponsored digital resource
30 Jan 2012 -
Approval in US for Pfizer's renal cancer drug Inlyta
FDA decisions comes on same day as bosutinib review initiated
30 Jan 2012 -
Pfizer's Mark Brincat joins Exco InTouch to lead its mHealth strategy
Brincat was the pharma company's former European healthcare informatics director
30 Jan 2012 -
Abbott cuts 700 US jobs as it prepares for a major restructure
Layoffs come despite steady net earnings for 2011
27 Jan 2012 -
ABPI: Nothing to stop pharma using social media
Provided it's done in a responsible way, says UK pharmaceutical industry body
27 Jan 2012 -
UK widens patient access to genomic cancer tests
Government will also consider Human Genomics Strategy Group’s genomic technology recommendations
27 Jan 2012 -
Amgen to buy German biotech Micromet for $1.16bn
Will gain Munich R&D centre and rights to haematologic cancer antibody blinatumomab
27 Jan 2012 -
BMS names Gerald Storch to board of directors
Chairman and CEO of Toys“R”Us brings retail experience to pharma company
27 Jan 2012 -
Horizon Discovery appoints Eric Rhodes as chief technical officer
Former Sangamo Biosciences VP of business development to join personalised medicine specialists
27 Jan 2012 -
Eisai launches breast cancer drug Halaven in Italy
Follows conclusion of reimbursement negotiations last year
26 Jan 2012 -
Boehringer's afatinib moves into phase III trials for head and neck cancer
Drug is potential challenge to ImClone, Bristol-Myers Squibb and Merck Serono’s Erbitux
26 Jan 2012 -
Ipsen hands back Parkinson’s drug fipamezole
Second time Santhera has rights returned by licensing partner
26 Jan 2012 -
Merck Serono’s Rebif approved in EU for early-stage MS
Boost for multiple sclerosis treatment in increasingly competitive market
26 Jan 2012 -
Allergan Botox tweet breaches UK pharma's Code of Practice
Company ruled to have breached Code over employee’s use of a personal Twitter account
26 Jan 2012 -
Novartis’ Q4 profit drops by half by ‘exceptional’ costs of $1.5bn
Rasilez/Tekturna impairment charges drag figures down, while sales see modest growth
26 Jan 2012 -
David Holliday joins Octapharma USA as VP commercial development
Moves from Baxter Bioscience to take up senior sales and marketing role in the US
26 Jan 2012 -
Roche makes offer of $5.7bn for genetics film Illumina
Company aims to strengthen position in diagnostics market through use of gene technology
25 Jan 2012 -
FDA review of Alexza’s Adasuve delayed
Inhaled antipsychotic drug's REMS delays FDA decision to May, 2012
25 Jan 2012 -
Charges bring J&J profit down by 89 per cent despite sales increase
Recalls and litigation totalling $2.86bn make their mark on US firm
25 Jan 2012 -
Watson buys Australian generics maker
US-based Generics company to pay AU$375m for Ascent Pharmahealth
25 Jan 2012 -
Boehringer to begin beta-testing Facebook game in March
Syrum's full launch delayed for improvements, including the addition of educational content
25 Jan 2012 -
Boehringer appoints Paul Fonteyne to lead US operations
He takes over from J Martin Carroll as president and CEO of Boehringer Ingelheim USA
25 Jan 2012 -
Premier Research appoints Dr Colin Hayward as European medical director
He will lead the company's European medical affairs and pharmacovigilance operations
25 Jan 2012 -
Novo Nordisk to establish type 1 diabetes research centre in Seattle
Facility will work with existing inflammation centre to find “new, innovative ways” to treat type 1 diabetes
24 Jan 2012 -
Galena starts registration for breast cancer vaccine trial
NeuVax aims to prevent recurrence in women ineligible for treatment with Roche’s Herceptin
24 Jan 2012 -
Cambridge University joins Lilly’s open-source discovery platform
UK academic institution will have access to pharma company’s in vitro model systems
24 Jan 2012 -
Pharma ‘neither leading nor lagging’ on Twitter
Benchmarking study counters some of the myths of pharmaceutical social media
24 Jan 2012 -
Dr Richard Barker joins Celgene's board of directors
Former ABPI director general takes up second new post this month
24 Jan 2012 -
Genzyme agrees thyroid cancer diagnostic deal with Veracyte
Sanofi-owned biotech to complement genomic diagnostic tool with its own Thyrogen product
24 Jan 2012 -
EMA calls for meprobamate sedatives to be suspended
Pfizer’s Equanil among medicines said to carry risk of serious side effects
23 Jan 2012 -
EMA launches consultation on biosimilar tests of interferon beta
Covers non-clinical and clinical requirements for versions of the multiple sclerosis drugs
23 Jan 2012 -
Safety of Novartis' MS drug Gilenya reviewed after 11 deaths
EMA review of cardiovascular effects of drug follows FDA reassessment
23 Jan 2012 -
US label change could boost Tysabri growth
Biogen Idec and Elan's multiple sclerosis drug can now be used with companion diagnostic to screen patients for side effect
23 Jan 2012 -
EMA recommends approval for Novartis Cushing’s disease drug Signifor
Puts it inline to become the first approved drug for the rare, life-threatening illness
23 Jan 2012 -
Takeda gains approval for hypertension drug Azilva in Japan
Regulators approve its once-daily angiotensin II receptor antagonist to treat high blood pressure
23 Jan 2012 -
Clinigen appoints Shaun Chilton as COO of services division
Former KnowledgePoint360 Group president and MD will head both Keats Healthcare and Clinigen GAP
23 Jan 2012
